<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Diabetic subjects have a high prevalence of <z:hpo ids='HP_0000822'>hypertension</z:hpo>, increased total body exchangeable <z:chebi fb="199" ids="26708">sodium</z:chebi> levels, and an impaired ability to excrete a <z:chebi fb="199" ids="26708">sodium</z:chebi> load </plain></SENT>
<SENT sid="1" pm="."><plain>This study assessed the effect of dietary <z:chebi fb="199" ids="26708">sodium</z:chebi> restriction on the efficacy of <z:chebi fb="0" ids="6541">losartan</z:chebi> in hypertensive subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and albumin excretion rates of 10-200 microg/min </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: In this study, 20 subjects were randomized to <z:chebi fb="0" ids="6541">losartan</z:chebi> 50 mg/day (n = 10) or placebo (n = 10) </plain></SENT>
<SENT sid="3" pm="."><plain>Drug therapy was given in two 4-week phases separated by a washout period </plain></SENT>
<SENT sid="4" pm="."><plain>In the last 2 weeks of each phase, patients were assigned to low- or regular-<z:chebi fb="199" ids="26708">sodium</z:chebi> diets, in random order </plain></SENT>
<SENT sid="5" pm="."><plain>In each phase, 24-h ambulatory blood pressure, urinary albumin-to-<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio (ACR), and renal hemodynamics were measured </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Achieved urinary <z:chebi fb="199" ids="26708">sodium</z:chebi> on a low-<z:chebi fb="199" ids="26708">sodium</z:chebi> diet was 85 +/- 14 and 80 +/- 22 mmol/day in the <z:chebi fb="0" ids="6541">losartan</z:chebi> and placebo groups, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>In the <z:chebi fb="0" ids="6541">losartan</z:chebi> group, the additional blood pressure-lowering effects of a low-<z:chebi fb="199" ids="26708">sodium</z:chebi> diet compared with a regular-<z:chebi fb="199" ids="26708">sodium</z:chebi> diet for 24-h systolic, diastolic, and mean arterial blood pressures were 9.7 mmHg (95% confidence interval [CI], 2.2-17.2; P = 0.002), 5.5 mmHg (2.6-8.4; P = 0.002), and 7.3 mmHg (3.3- 11.3; P = 0.003), respectively </plain></SENT>
<SENT sid="8" pm="."><plain>In the <z:chebi fb="0" ids="6541">losartan</z:chebi> group, the ACR decreased significantly on a low-<z:chebi fb="199" ids="26708">sodium</z:chebi> diet versus on a regular-<z:chebi fb="199" ids="26708">sodium</z:chebi> diet (-29% [CI -50.0 to -8.5%] vs. + 14% [-19.4 to 47.9%], respectively; P = 0.02) </plain></SENT>
<SENT sid="9" pm="."><plain>There was a strong correlation between fall in blood pressure and percent reduction in the ACR (r = 0.7, P = 0.02) </plain></SENT>
<SENT sid="10" pm="."><plain>In the placebo group, there were no significant changes in blood pressure or ACR between regular- and low-<z:chebi fb="199" ids="26708">sodium</z:chebi> diets </plain></SENT>
<SENT sid="11" pm="."><plain>There were no significant changes in renal hemodynamics in either group </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: These data demonstrated that a low-<z:chebi fb="199" ids="26708">sodium</z:chebi> diet potentiates the <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> and antiproteinuric effects of <z:chebi fb="0" ids="6541">losartan</z:chebi> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain>The blood pressure reduction resulting from the addition of a low-<z:chebi fb="199" ids="26708">sodium</z:chebi> diet to <z:chebi fb="0" ids="6541">losartan</z:chebi> was of similar magnitude to that predicted from the addition of a second <z:chebi fb="0" ids="35674">antihypertensive agent</z:chebi> </plain></SENT>
</text></document>